BCWORLD PHARM. Co., Ltd.
Financials
Valuation Metrics
BCWORLD PHARM. Co., Ltd.'s Market Cap is ₩299B. At end of 2025 it was ₩588B. Ranked #2037 of 2,405 in KR market (top 85%), #1294 of 1,627 on KOSDAQ (top 80%), #213 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 92%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 29.92B KRW | KR#2,037/2,405 Sec#213/231 |
| Revenue | 80.33B KRW | KR#1,545/2,405 Sec#98/231 |
| Net Income | -1.26B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 176.80B KRW | KR#1,391/2,405 Sec#104/231 |
| Net Assets | 72.50B KRW | KR#1,653/2,405 Sec#138/231 |
| Employees | 281 | KR#839/2,405 Sec#71/231 |
| Value | ||
| P/B | 0.41x | KR#681/2,405 Sec#25/231 |
| P/S | 0.37x | KR#770/2,405 Sec#25/231 |
| EV/EBITDA | 39.56x | KR#1,303/2,405 Sec#84/231 |
| Profitability | ||
| ROE | -1.74% | KR#1,668/2,405 Sec#115/231 |
| ROA | -0.71% | KR#1,636/2,405 Sec#112/231 |
| Op. Margin | 3.51% | KR#1,160/2,405 Sec#85/231 |
| Revenue Growth | 6.65% | KR#1,089/2,405 Sec#107/231 |
| Earnings Growth | -181.78% | KR#1,223/2,405 Sec#82/231 |
| Financial Health | ||
| Debt Ratio | 143.86% | KR#1,861/2,405 Sec#205/231 |
| Total Debt | 87.53B KRW | KR#776/2,405 Sec#48/231 |
| Cash | 5.88B KRW | KR#1,945/2,405 Sec#176/231 |
| Current Ratio | 0.53x | KR#2,114/2,405 Sec#204/231 |
| Net Debt/EBITDA | 28.95x | KR#1,425/2,405 Sec#101/231 |
| Dividend | ||
| Div. Yield | 3.23% | KR#628/2,405 Sec#28/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -34.19% | KR#1,567/2,405 Sec#126/231 |
| 1M Return | -8.03% | KR#988/2,405 Sec#94/231 |
| From 52W High | -53.48% | KR#1,326/2,405 Sec#106/231 |
| 1Y MDD | -52.47% | KR#1,065/2,405 Sec#87/231 |
| Trading | ||
| Volume | 9,358 shares | KR#1,867/2,405 Sec#188/231 |
| Trading Value | 26.2M KRW | KR#2,004/2,405 Sec#207/231 |
| Foreign Own. | 1.21% | KR#1,932/2,405 Sec#190/231 |
| Per Share | ||
| EPS | -119 KRW | KR—/2,405 Sec—/231 |
| BPS | 6,798 KRW | KR#1,278/2,405 Sec#90/231 |
Company Info
BC World Pharm, established in 1980 and renamed in 2007, was certified as an innovative pharmaceutical company in 2012, a status it holds until 2024. The company specializes in pharmaceutical manufacturing and sales, leveraging EU GMP/cGMP-level facilities to expand its domestic and international Contract Manufacturing Organization (CMO)/Contract Development and Manufacturing Organization (CDMO) businesses and exports to advanced and emerging markets. As an R&D-focused pharmaceutical company with original Drug Delivery System (DDS) technology, it invests about 12% of its sales into R&D, growing into a global healthcare enterprise. BC World Pharm is headquartered in Gyeonggi-do, Yeoju-si.